Difference between revisions of "Lung carcinoma with EGFR mutation"
Jump to navigation
Jump to search
| Line 52: | Line 52: | ||
==See also== | ==See also== | ||
*[[Lung carcinoma with ALK rearrangement]]. | *[[Lung carcinoma with ALK rearrangement]]. | ||
*[[Epidermal growth factor receptor inhibitors]]. | |||
==References== | ==References== | ||
Revision as of 17:44, 18 June 2017
Lung adenocarcinoma with EGFR rearrangement is a molecular subtype of lung adenocarcinoma.
General
- EGFR mutations are most closely associated with lung adenocarcinoma.
- Testing indicated in non-small cell carcinoma, adenosquamous carcinoma of the lung, as well as lung adenocarcinoma.
Varies significantly by population:[1]
| Population | Prevalence | Category |
|---|---|---|
| Europe | 14% | Geographic |
| China | 38% | Geographic |
| Females | 44% | Patient characteristics |
| Males | 24% | Patient characteristics |
| Non-smokers | 49% | Patient characteristics |
| Smokers or past smokers | 22% | Patient characteristics |
| Adenocarcinoma | 38% | Pathology |
| Non-adenocarcinoma | 12% | Pathology |
Sign out
Lung core biopsy, left lower lobe: - EGFR mutation POSITIVE, ALK rearrangement NEGATIVE
See also
References
- ↑ Zhang, YL.; Yuan, JQ.; Wang, KF.; Fu, XH.; Han, XR.; Threapleton, D.; Yang, ZY.; Mao, C. et al. (Nov 2016). "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.". Oncotarget 7 (48): 78985-78993. doi:10.18632/oncotarget.12587. PMID 27738317.